Urenco increases its stable isotopes offering

Urenco is taking a considerable step forward in the production of stable isotopes in 2021.

The growing market in this field has led us to expand our facility to meet the demand, especially for products in the medical and the semiconductor field.

One of the products, Xenon 129, will be used in MRI imaging to detect lung diseases. We are also doing research to support solutions for cancer treatment. Already, hundreds of thousands of patients are treated every year with products made from our enriched stable isotopes. Other applications of our products are very varied and include super-fast computer processing power development and experimental research programmes which search for the ultra-rare neutrino-less double-beta decay.

This demonstrates the versatility of our centrifuge technology, which is not limited to the separation of uranium isotopes. It can also be used for the separation of other isotopes – including cadmium, germanium, iridium, molybdenum, selenium, tellurium, titanium, tungsten, xenon and zinc – for medical, industrial and research applications.

We have gained expertise in this area for over three decades at our enrichment facility in the Netherlands, supporting the improvement of medical diagnostics, therapy, and many other fields, and building a substantial portfolio of enriched and depleted products for a wide range of markets and customers.

Martijn van Hezel, Commercial Manager Stable Isotopes, said: “We are looking forward to working with customers on new research and development projects, producing high-quality, cost-efficient products and solutions that will change lives and thrive prosperity.”

Share Article